Curriculum vitae for mark cushman - Purdue College of Pharmacy ...

18
Mark Cushman
252. Y. L. Song and M. Cushman, "The Binding Orientation of a Norindenoisoquinoline in the
Topoisomerase I-DNA Cleavage Complex Is Primarily Governed by π-π Stacking
Interactions," J. Phys. Chem. B 112, 9484-9489 (2008).
253. M. Cuendet, C. P. Oteham, A. Maiti, B. A. Craig, M. Cushman, R. C. Moon and J. M.
Pezzuto, "Zapotin Prevents Mouse Skin Tumorigenesis During the Stages of Initiation
and Promotion," Anticancer Res. 28, 3705-3709 (2008).
254. T.-Y. Yu, R. D. O'Connor, A. C. Sivertsen, C. Chiauzzi; B. Poliks, M. Fischer, A.
Bacher, I. Hasse, and M. Cushman, J. Schaefer," 15 N{ 31 P} REDOR NMR Studies of the
Binding of Phosphonate Reaction Intermediate Analogues to Saccharomyces cerevisiae
Lumazine Synthase," Biochemistry 47, 13942-13951 (2008).
255. R. P. Bakshi, D. Sang, A. Morrell, M. Cushman, and T. A. Shapiro, "Activity of
Indenoisoquinolines against African Trypanosomes," Antimicrob. Agents Chemother. 53,
123-128 (2009).
256. Y. Pommier and M. Cushman, "The Indenoisoquinoline Non-Camptothecin
Topoisomerase I Inhibitors: Update and Perspectives." Mol. Cancer Ther. 8, 1008-1014
(2009).
257. B.-L. Deng, Y. Zhao, T. L. Hartman, K. Watson, R. W. Buckheit Jr., C. Pannecouque, E.
De Clercq, and M. Cushman, "Synthesis of Alkenyldiarylmethanes (ADAMs)
Containing Benzo[d]isoxazole and Oxazolidin-2-one Rings, a New Series of Potent Nonnucleoside
HIV-1 Reverse Transcriptase Inhibitors," Eur. J. Med. Chem. 44, 1210-1214
(2009).
258. A. Maiti, M. Sturdy, L. Marler, S. D. Pegan, A. Mesecar, J. M. Pezzuto, and M.
Cushman, "Synthesis of Casimiroin and Optimization of Its Quinone Reductase 2 and
Aromatase Inhibitory Activity," J. Med. Chem. 52, 1873-1884 (2009).
259. Y. Zhao, A. Bacher, B. Illarionov, M. Fischer, G. Georg, Q.-Z. Ye, P. E. Fanwick, S. G.
Franzblau, B. Wan, and M. Cushman, "Discovery and Development of the Covalent
Hydrates of Trifluoromethylated Pyrazoles as Riboflavin Synthase Inhibitors with
Antibiotic Activity Against Mycobacterium tuberculosis," J. Org. Chem. 74, 5297-5303
(2009).
260. A. Talukdar, M. Breen, A. Bacher, B. Illarionov, M. Fischer, G. Georg, Q.-Z. Ye, and M.
Cushman, "Discovery and Development of a Small Molecule Library with Lumazine
Synthase Inhibitory Activity," J. Org. Chem. 74, 5123-5134 (2009).
261. M. A. Cinelli, B. Cordero, T. S. Dexheimer, Y. Pommier, and M. Cushman, "Synthesis
and Biological Evaluation of 14-(Aminoalkyl-aminomethyl)aromathecins as
Topoisomerase I Inhibitors: Investigating the Hypothesis of Shared Structure-Activity
Relationships," Bioorg. Med. Chem. 17, 7145-7155 (2009).
262. M. D. Cullen, W. C. Ho, J. D. Bauman, K. Das, E. Arnold, T. Hartman, K. M. Watson, R.
W. Buckheit, C. Pannecouque, E. De Clercq, and M. Cushman, "Crystallographic Study
of a Novel Subnanomolar Inhibitor Provides Insight on the Binding Interactions of
Alkenyldiarylmethanes with Human Immunodeficiency Virus-1 Reverse Transcriptase,"
J. Med. Chem. 52, 6467-6473 (2009).
263. Z. Fang, G. E. Agoston, G. Ladouceur, A. Treston, L. Wang, and M. Cushman,
"Structure Elucidation by Synthesis of Four Metabolites of the Antitumor Drug ENMD-
1198 Detected in Human Plasma Samples," Tetrahedron 65, 10535-10543 (2009).
264. Y. Song, A. Shao, T. S. Dexheimer, E. S. Scher, Y. Pommier, and M. Cushman,
"Structure-Based Design, Synthesis, and Biological Studies of New Anticancer
Norindenoisoquinoline Topoisomerase I Inhibitors," J. Med. Chem. 53, 1979-1989
(2010).